Anadolu Medical Center
| Turkey | Thailand | South Korea | |
| Proton-beam therapy | from AUD $101,543 | from AUD $130,555 | from AUD $31,914 |
| Chemotherapy for breast cancer | from AUD $1,741 | from AUD $4,352 | from AUD $27,852 |
| Proton therapy for prostate cancer | from AUD $43,518 | from AUD $65,278 | - |
| Proton therapy for breast cancer | from AUD $43,518 | from AUD $72,531 | - |
| Bone resection | from AUD $11,605 | from AUD $17,407 | - |
Dr. Bulent Karagoz is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in immunotherapy and targeted therapies for sarcoma, lymphoma, and lung cancer. Dr. Karagoz provides treatment at a facility affiliated with the prestigious Johns Hopkins Hospital.
Dr. Mustafa Solak is a clinical oncologist at Hisar Hospital Intercontinental in Istanbul. He completed a fellowship at the prestigious Hacettepe University Cancer Institute. Dr. Solak previously practiced at The University of Texas MD Anderson Cancer Center. He treats a variety of complex cancers, including lung, breast, and gastrointestinal malignancies.
Dr. Banu Atalar is a board-certified radiation oncologist (Türkiye, 2004). She is a Full Professor at Acibadem MAA University (2018–present) and a clinician at Anadolu Medical Center (2026–present). She trained at Istanbul and Cerrahpaşa. In 2011, she completed a Stanford clinical research fellowship in stereotactic radiosurgery. Her practice focuses on CNS, thoracic, and GI tumors. About 75% of her care involves SRS and MR‑guided adaptive SRS.
Her honors include the ASCO IDEA award (2004), the IASLC International Mentorship Award (2018), and H.FACR (2025). She has 72 international peer‑reviewed publications. Her leadership roles include President of the Turkish Society for Radiation Oncology (2025–27) and Chair of the ESTRO National Societies Committee (2024–27). She served on the ASCO Resource‑Stratified Guidelines Committee (2013–18) and on RSS meeting and nomination committees. She organized national congresses (2023, 2025) and has been an invited speaker at major meetings.
Dr. Mehmet Taner Ozdemir is an orthopedist and bone tumor specialist at Anadolu Medical Center. He completed training at the Hospital for Special Surgery in New York. This facility is a top-ranked center for orthopedics in the United States. Dr. Ozdemir focuses on orthopedic oncology and complex trauma surgery.
Turkish surgeons are highly experienced in treating chondrosarcoma. Specialists often hold 20+ years of oncology experience. Major centres in Istanbul and Ankara perform complex tumour resections and limb-salvage surgeries. These facilities use JCI-accredited protocols and imaging to manage rare bone sarcomas.
Bookimed Expert Insight: Turkish orthopaedic oncologists often hold memberships in the European Musculoskeletal Tumor Society. Dr Mehmet Taner Ozdemir is an example. This connection is vital because chondrosarcoma requires highly specific surgical margins. Data shows these specialists often complete fellowships at top-tier US institutions. They bring surgical techniques to Istanbul's JCI-accredited hospitals.
Patient Consensus: Patients report high satisfaction with the medical service and clinical results at major Istanbul centres. Some note that costs at premier clinics are significant. However, they value the professional support and high-quality care received in Turkey.
Turkey is a high-quality destination for chondrosarcoma treatment. This is due to its JCI-accredited oncology centres and multidisciplinary expert teams. Specialist surgeons perform complex bone resections, while oncologists provide targeted therapies and specialised radiation. Patients typically access surgical treatment within 1–2 weeks.
Bookimed Expert Insight: While many patients focus on surgery, the standard of follow-up care distinguishes top Turkish centres. Facilities like Anadolu Medical Center maintain a formal affiliation with Johns Hopkins Hospital. This means their sarcoma protocols align with American clinical standards. This is particularly valuable for chondrosarcoma cases. These require precise imaging to monitor for local recurrence over several years.
Patient Consensus: Patients are generally satisfied with the oncology services and technical results in Turkey. They often note that complex diagnostics are handled efficiently. However, they suggest confirming all inclusions in treatment plans before arrival.
Surgical resection is the primary treatment for chondrosarcoma in Turkey. Specialists focus on removing the tumour with clean margins. This approach is essential because these bone cancers are typically resistant to traditional chemotherapy and radiation. Specialised centres often use limb-sparing techniques.
Bookimed Expert Insight: Turkish oncology centres like Anadolu Medical Center are directly affiliated with Johns Hopkins Hospital. This allows surgeons to use US-standard multidisciplinary tumour boards for rare bone sarcomas. Patients benefit from American-level treatment protocols at Turkish price points. These price points often include preoperative tests and consultations.
Patient Consensus: Patients note that while treatment results are successful, costs vary significantly across Istanbul clinics. Many highlight that a personal coordinator helps manage the logistics of sarcoma surgery in Turkey.
Radiation therapy is available for chondrosarcoma in Turkey at major JCI-accredited oncology centres. Specialists use TrueBeam STx and Halcyon systems for high-precision treatment. Surgery remains the primary curative option. However, radiation serves as an adjunct for mesenchymal subtypes or palliative care.
Bookimed Expert Insight: Turkish oncology centres like Anadolu Medical Center maintain affiliations with leading international institutions like Johns Hopkins Hospital. This allows patients to access American-standard radiation protocols for rare sarcomas. Standard radiation has limited impact on most chondrosarcomas. However, these centres offer conformal radiotherapy that protects healthy tissue during intensive treatment.
Patient Consensus: Patients note that surgery is the mainstay for chondrosarcoma in Turkey. However, the availability of imaging like PET-MRI helps specialists plan precise radiation for complex cases.
Patients typically stay in Turkey for 2 to 3 weeks to complete the surgical phase of chondrosarcoma treatment. This timeframe includes 3 days for diagnostics. A 7-day hospital stay is typical for bone resection. It also allows 7 days of local recovery before flying home. Stays extend if proton-beam therapy or immunotherapy is required.
Bookimed Expert Insight: While surgical stays are standard, travel times vary by tumour location. Patients undergoing chest wall reconstruction should allow extra recovery time. This is especially important with surgeons like Dr Hasan Fevzi Batirel at Memorial Göztepe. This extra time allows lung function to stabilise. Then it can handle the cabin pressure of a long-haul flight back to Australia.
Patient Consensus: Patients find the transition smooth. Clinics like Anadolu Medical Center provide personal interpreters and airport transfers. This support helps manage the 3-week stay without logistical stress in Istanbul.